Table 1
Demographics of survey respondents. N refers to number of respondents.
| DEMOGRAPHIC VARIABLES | N | % |
|---|---|---|
| Age | ||
| 25–35 | 106 | 31 |
| 36–45 | 116 | 33 |
| 46–55 | 68 | 20 |
| 56–65 | 39 | 11 |
| ≥66 | 17 | 5 |
| Years in practice | ||
| ≤5 yr | 101 | 29 |
| 6–10 yr | 69 | 20 |
| 11–15 yr | 60 | 17 |
| 16–20 yr | 41 | 12 |
| ≥21 yr | 74 | 22 |
| Type of practice | ||
| Academic clinician in a hospital | 249 | 72 |
| Academic clinician in a community service | 61 | 18 |
| Non-academic clinician in a hospital | 20 | 6 |
| Non-academic clinician in a community service | 15 | 4 |
| Number of patients seen | ||
| No patients | 32 | 9 |
| 1–10 per year | 193 | 56 |
| 1–10 per month | 84 | 24 |
| >10 per month | 37 | 11 |
| Patient profile | ||
| Exclusively or mostly adults | 125 | 43 |
| Adults and pediatric | 110 | 37 |
| Exclusively or mostly pediatric | 59 | 20 |
| Continent (N = participants) | ||
| Europe | 129 | 38 |
| The Americas | 115 | 33 |
| Asia | 72 | 21 |
| Africa | 25 | 7 |
| Oceania | 2 | 1 |
Figure 1
Factors supporting a diagnosis of functional tic disorder. Total number of respondents: n = 245.
Figure 2
Perceptions on tic pathophysiology. Total number of respondents: n = 248.
Figure 3
Opinions on treatment efficacy of different interventions. Total number of respondents: n = 231.
Table 2
Top 5 selected medications used to treat tics in adults and children/adolescents.
| ADULTS | N* | CHILDREN/ADOLESCENTS (N) | N* |
|---|---|---|---|
| Risperidone | 129 | Risperidone | 121 |
| Aripiprazole | 126 | Aripiprazole | 114 |
| Clonidine | 105 | Clonidine | 110 |
| Tetrabenazine | 100 | Topiramate | 76 |
| Haloperidol | 88 | Haloperidol | 75 |
[i] * = Total number of responses for adults = 220, for children/adolescents = 197.